IMUNON, Inc. announced on June 18, 2025, the presentation of new positive translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the ESMO Gynaecological Cancers Congress 2025 in Vienna, Austria. The results reinforced IMNN-001's mechanism of action, demonstrating its ability to produce IL-12 and key anti-cancer immune cytokines in the tumor microenvironment.
Specifically, treatment with IMNN-001 induced substantial increases in IL-12, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels in the peritoneal fluid cavity, with approximately 27-, 62-, and 36-fold increases, respectively. This localized effect was observed with minimal systemic exposure, supporting the favorable safety profile of IMNN-001.
These translational findings strongly complement the compelling overall survival results from the OVATION 2 trial presented at ASCO 2025, validating that IMNN-001 effectively converts the tumor microenvironment from 'cold' to 'hot.' IMUNON is currently advancing its Phase 3 pivotal trial of IMNN-001, with the first two sites initiated in May 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.